Search

Displaying results 2001 - 2010 of 3734 in total
  1. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    [L42725] It is advantageous over currently available management therapies for PKU, such as [DB00360], that are ineffective to many patients due to long-term adherence issues or inadequate Phe-lowering

  2. Drug

    IMM-101

    go.drugbank.com/drugs/DB15850
    Investigational

    As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

  3. Drug

    Tozinameran

    go.drugbank.com/drugs/DB15696
    ApprovedInvestigational

    [L15027] On December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) based on 95% efficacy in clinical trials and a similar safety profile to other viral vaccines over a span of approximately

  4. Target

    ATP-binding cassette sub-family C member 9

    go.drugbank.com/bio_entities/BE0000469
    TargetHumans

    Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation (PubMed:9831708). Can form a sulfo...

    Synonyms: Sulfonylurea receptor 2
  5. Target

    NKG2-D type II integral membrane protein

    go.drugbank.com/bio_entities/BE0010415
    TargetHumans

    Acts as a costimulatory receptor for T-cell receptor (TCR) in CD8(+) T-cell-mediated adaptive immune responses by amplifying T-cell activation. … Functions as an activating and costimulatory receptor involved in immunosurveillance upon binding to various cellular stress-inducible ligands displayed at the surface of autologous tumor cells and virus-infected

    Synonyms: NK cell receptor D, NKG2-D-activating NK receptor
  6. Drug

    Lysergic acid diethylamide

    go.drugbank.com/drugs/DB04829
    IllicitInvestigational

    Debate continues over the nature and causes of chronic flashbacks.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.

  8. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    [L45793,L43130] For over a decade, bevacizumab was also used off-label by intravitreal injection to treat neovascular (wet) age-related macular degeneration and other retinal conditions, repackaged from

    Categories: VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors
  9. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    The unrelated donor transplant setting has several advantages over related donor transplant and bone marrow transplantation; it allows shorter time to transplant and tolerance of 1–2 human leukocyte antigen

  10. Target

    Transmembrane anterior posterior transformation protein 1 homolog

    go.drugbank.com/bio_entities/BE0003506
    TargetHumans

    Plays a role in primary cilia formation (PubMed:26365339). May act as a downstream effector of HOXC8 possibly by transducing or transmitting extracellular information required for axial skeletal patterning during development (By similari...

    Synonyms: Cytomegalovirus partial fusion receptorFunction: growth hormone-releasing hormone receptor activity